PARP inhibitors: Synthetic lethality in the clinic
Top Cited Papers
- 17 March 2017
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 355 (6330), 1152-1158
- https://doi.org/10.1126/science.aam7344
Abstract
PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago. Tumors arising in patients who carry germline mutations in either BRCA1 or BRCA2 are sensitive to PARPi because they have a specific type of DNA repair defect. PARPi also show promising activity in more common cancers that share this repair defect. However, as with other targeted therapies, resistance to PARPi arises in advanced disease. In addition, determining the optimal use of PARPi within drug combination approaches has been challenging. Nevertheless, the preclinical discovery of PARPi synthetic lethality and the route to clinical approval provide interesting lessons for the development of other therapies. Here, we discuss current knowledge of PARP inhibitors and potential ways to maximize their clinical effectiveness.Keywords
Funding Information
- Breast Cancer Now
- Cancer Research UK
This publication has 73 references indexed in Scilit:
- A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib ToxicityPLOS ONE, 2013
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionCancer Discovery, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast CancerClinical Cancer Research, 2010
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical TargetsMolecular Cell, 2010
- Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesisNature Reviews Molecular Cell Biology, 2010
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995
- Role of poly(ADP-ribose) formation in DNA repairNature, 1992